Literature DB >> 29080197

Scutellaria barbata D. Don inhibits colorectal cancer growth via suppression of Wnt/β-catenin signaling pathway.

Li-Hui Wei1,2, Jiu-Mao Lin1,2, Jian-Feng Chu1,2, Hong-Wei Chen1,2, Qing-Yu Li1,2, Jun Peng3,4.   

Abstract

OBJECTIVE: To investigate the effect of the ethanol extract of Scutellaria barbata D. Don (EESB) on colorectal cancer (CRC) growth and Wnt/β-catenin signaling pathway in vivo and in vitro.
METHODS: In vivo experiment, CRC xenograft mouse model was constructed with injection of HT-29 cells. Following xenograft implantation, twenty mice were randomly divided into EESB-treated group (n=10) and control group (n=10) by a random number table, and were given with intra-gastric administration of 2 g/kg EESB or saline, 5 days a week for 16 days, respectively. At the end of experiment, tumors were removed and weighed by electronic scales. The proliferation biomarker Ki-67 of tumor was evaluated by immunohistochemistry (IHC) assay. In vitro study, HT-29 cells were treated with 0, 0.5, 1.5, 2.5 mg/mL EESB for 24 h. At the end of the treatment, the viability and survival of HT-29 cells were determined by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay and colony formation assay, respectively. The mRNA expression of c-Myc, Survivin and adenomatous polyposis coli (APC) was examined by reverse transcription-polymerase chain reaction (RT-PCR) both in tumor tissues of CRC xenograft mice and HT-29 cells. Protein expression of c-Myc, Survivin, APC, and β-catenin as well as β-catenin phosphorylation level were evaluated by IHC assay or Western blotting.
RESULTS: EESB significantly reduced tumor weight in CRC xenografts mice, compared with the control group (P<0.05). IHC assay showed that EESB significantly inhibited protein expression of Ki-67 in tumor tissues (P<0.05). MTT assay showed that EESB significantly reduced HT-29 cell viability in a dose-dependent manner (P<0.05). Colony formation assay showed that EESB dose-dependently decreased the survival of HT-29 cells (P<0.05). In addition, RT-PCR assay showed that EESB decreased the mRNA expression of c-Myc and Survivin and increased APC expression, both in tumor tissues of CRC xenograft mice and HT-29 cells (P<0.05). IHC assay or Western blotting showed that EESB decreased protein expression of β-catenin, c-Myc and Survivin, as well as increased APC expression and β-catenin phosphorylation in tumor tissues or HT-29 cells (P<0.05).
CONCLUSIONS: EESB significantly reduced tumor growth in CRC xenografts mice, and inhibited the viability and survival of HT-29 cells. EESB could suppress the activation of the Wnt/β-catenin pathway, which might be one of the mechanisms whereby Scutellaria barbata D. Don exerts its anticancer activity.

Entities:  

Keywords:  Scutellaria barbata D. Don; Wnt/β-catenin pathway; colorectal cancer; proliferation

Mesh:

Substances:

Year:  2017        PMID: 29080197     DOI: 10.1007/s11655-017-2775-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  23 in total

Review 1.  The Wnt signaling pathway in development and disease.

Authors:  Catriona Y Logan; Roel Nusse
Journal:  Annu Rev Cell Dev Biol       Date:  2004       Impact factor: 13.827

Review 2.  An updated overview on Wnt signaling pathways: a prelude for more.

Authors:  Tata Purushothama Rao; Michael Kühl
Journal:  Circ Res       Date:  2010-06-25       Impact factor: 17.367

Review 3.  Angiogenesis in cancer - general pathways and their therapeutic implications.

Authors:  Ivanka Dimova; Georgi Popivanov; Valentin Djonov
Journal:  J BUON       Date:  2014 Jan-Mar       Impact factor: 2.533

Review 4.  The Wnt pathway: emerging anticancer strategies.

Authors:  Aman Gupta; Anukriti Verma; Ashutosh K Mishra; Gulshan Wadhwa; Sanjeev K Sharma; Chakresh K Jain
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2013-05

Review 5.  Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch.

Authors:  Fred E Bertrand; C William Angus; William J Partis; George Sigounas
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

6.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

7.  Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549.

Authors:  Xiaolu Yin; Jiangbing Zhou; Chunfa Jie; Dongming Xing; Ying Zhang
Journal:  Life Sci       Date:  2004-09-17       Impact factor: 5.037

8.  Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Karl-Anton Kreuzer
Journal:  Eur J Cancer       Date:  2009-09-02       Impact factor: 9.162

Review 9.  Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?

Authors:  David P Minde; Zeinab Anvarian; Stefan Gd Rüdiger; Madelon M Maurice
Journal:  Mol Cancer       Date:  2011-08-22       Impact factor: 27.401

Review 10.  Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Authors:  Tomoya Yokota
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

View more
  9 in total

Review 1.  How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?

Authors:  Yulia Kirdeeva; Olga Fedorova; Alexandra Daks; Nikolai Barlev; Oleg Shuvalov
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-14

2.  Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells.

Authors:  Fang-Rui Liu; Shuang Bai; Qiang Feng; Xin-Yan Pan; Shu-Ling Song; Hong Fang; Jing Cui; Ju-Lun Yang
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

Review 3.  Therapeutic Effects of Ten Commonly Used Chinese Herbs and Their Bioactive Compounds on Cancers.

Authors:  Wei Liu; Binbin Yang; Lu Yang; Jasmine Kaur; Calvin Jessop; Rushdi Fadhil; David Good; Guoying Ni; Xiaosong Liu; Tamim Mosaiab; Zhengjun Yi; Ming Q Wei
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-15       Impact factor: 2.629

Review 4.  Small Molecule Wnt Pathway Modulators from Natural Sources: History, State of the Art and Perspectives.

Authors:  Artem Blagodatski; Antonina Klimenko; Lee Jia; Vladimir L Katanaev
Journal:  Cells       Date:  2020-03-02       Impact factor: 6.600

Review 5.  Regulation of Hedgehog Signaling by miRNAs and Nanoformulations: A Possible Therapeutic Solution for Colorectal Cancer.

Authors:  Zeeshan Javed; Muhammad Javed Iqbal; Amna Rasheed; Haleema Sadia; Shahid Raza; Asma Irshad; Wojciech Koch; Wirginia Kukula-Koch; Anna Głowniak-Lipa; William C Cho; Javad Sharifi-Rad
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

6.  Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Authors:  Yong Ji; Jian Lv; Di Sun; Yufeng Huang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

Review 7.  Traditional Chinese Medicines as Effective Reversals of Epithelial-Mesenchymal Transition Induced-Metastasis of Colorectal Cancer: Molecular Targets and Mechanisms.

Authors:  Hongzhang Ge; Chao Xu; Haitao Chen; Ling Liu; Lei Zhang; Changhong Wu; Yi Lu; Qinghua Yao
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

8.  Antitumor Effects and the Compatibility Mechanisms of Herb Pair Scleromitrion diffusum (Willd.) R. J. Wang-Sculellaria barbata D. Don.

Authors:  Li Lu; Sheng Zhan; Xiaohui Liu; Xin Zhao; Xiukun Lin; Huanli Xu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

9.  Comparison between Heat-Clearing Medicine and Antirheumatic Medicine in Treatment of Gastric Cancer Based on Network Pharmacology, Molecular Docking, and Tumor Immune Infiltration Analysis.

Authors:  Jiamin Xu; Fuqin Kang; Wei Wang; Shujun Liu; Jianhui Xie; Xiaobo Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-11       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.